6 Nov 2017 BAARN (Boston Area Antimicrobial Resistance Network) + 7-8 Nov BARDA Industry Days

Dear All:

Early November will be busy! First, BAARN is having their annual meeting in the Boston area on 6 Nov. See below a note from Michael Gilmore with details. If you are in Boston on that day, I highly recommend this meeting as a superb scientific event & networking opportunity.

Second, you can then go from BAARN to BARDA’s Industry Days in DC on 7-8 Nov. Here’s the registration link for more details. This is an opportunity to learn about BARDA’s strategic goals for FY18 and beyond while networking with members of ASPR, BARDA, AMCG and other government and industry stakeholders. If you are consider US government funding, this is a great way to learn about working with BARDA and its USG partners.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Mike writes: Tickets for the 2017 annual Boston Area Antibiotic Resistance Network meeting are now available at this link. The event will be on 6 Nov 2017 at the American Academy of Arts and Science’s Norton Woods Conference Center, adjacent to the Harvard campus (200 Beacon St., Somverville MA). The auditorium is limited to 200 attendees, so register early and notify friends and associates you know to be interested.

In response to feedback from last year, there will be more opportunity for 1-on-1 networking throughout the day. There will also be a rapid fire session for new biotechs to introduce their new efforts to the community.

The program:
8:00 – 8:30 Registration
8:30  Welcome

8:35 Session I: Advances in new therapeutics
10:15 – 11:00 Networking over coffee

11:00  Session II: Advances in alternatives to antibiotics for managing host microbe interactions
12:15 Lunch and more networking

2:00  Session III: Advances in Diagnostics
3:40 – 4:00 Short Break

4:00  Federal resources that can help (NIH Research Resources & Translational. Research DMID)
4:30  Short poster pitches from select treatment or diagnostic biotech startups

5:15 Networking and posters
7:00 Adjourn

​——————————
Upcoming meetings of interest to the AMR community:

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top